breast adjuvant chemotherapy
TRANSCRIPT
In general, when using chemotherapy in the In general, when using chemotherapy in the adjuvant setting for patients with adjuvant setting for patients with smaller, smaller,
node-negativenode-negative, HER2-negative tumors,, HER2-negative tumors, what tends to be the most common what tends to be the most common
regimen you use?regimen you use?
20072006
10%8%Other
Clinical investigators (CI)
4%
6%
41%*
39%
9%CMF
7%
60%
16%
AC/taxane regimens
AC
TC
* 14% of CIs use dose-dense AC
In general, when using chemotherapy In general, when using chemotherapy in the adjuvant setting for patients with in the adjuvant setting for patients with smaller, smaller, node-negativenode-negative, HER2-negative , HER2-negative
tumors,tumors, what tends to be the most common what tends to be the most common regimen you use?regimen you use?
20072006
2%9%Other
Practicing oncologists (PO)
5%
20%
52%*
21%
4%CMF
19%
65%
3%
AC/taxane regimens
AC
TC
* 9% of POs use dose-dense AC
In general, when using chemotherapy in In general, when using chemotherapy in the adjuvant setting for patients with the adjuvant setting for patients with
node-positivenode-positive, HER2-negative tumors,, HER2-negative tumors, what tends to be the most common what tends to be the most common chemotherapy regimen you use? chemotherapy regimen you use?
20072006
Clinical investigators (CI)
17%9%Other
0%
20%
0%
63%
4%AC ➙ docetaxel q3wk
16%
0%
71%
TAC
AC ➙ paclitaxel q3wk
Dose-dense AC ➙ paclitaxel q2wk
In general, when using chemotherapy in In general, when using chemotherapy in the adjuvant setting for patients with the adjuvant setting for patients with
node-positivenode-positive, HER2-negative tumors,, HER2-negative tumors, what tends to be the most common what tends to be the most common chemotherapy regimen you use? chemotherapy regimen you use?
20072006
20%6%Other
Practicing oncologists (PO)
7%
12%
7%
54%
10%AC ➙ docetaxel q3wk
13%
20%
51%
TAC
AC ➙ paclitaxel q3wk
Dose-dense AC ➙ paclitaxel q2wk
What percent of your patients with What percent of your patients with node-negativenode-negative breast cancer who breast cancer who
receive adjuvant chemotherapy receive receive adjuvant chemotherapy receive regimens that include taxanes?regimens that include taxanes?
200720062005
44%38%28%Mean
Practicing oncologists (PO)
Clinical investigators (CI)
58%32% 40%Mean
* All participants other than 2 POs had heard about the study.
Where have you received information about Where have you received information about TC as reported by the US Oncology Group? TC as reported by the US Oncology Group?
(May have more than one response)*(May have more than one response)*
25%6%Reading another journal or print piece
20%
27%
73%
84%
21%Other live or enduring continuing education programs
39%
61%
18%
Listening to audio interviews or roundtable discussions in the Breast Cancer Update series
Reading the Journal of Clinical Oncology
Attending the 2005 San Antonio Breast Cancer Symposium
Clinical investigators Practicing oncologists
Have you utilized the adjuvant TC regimen?Have you utilized the adjuvant TC regimen?
20072006
55%23%Percent answering yes
Practicing oncologists (PO)
Clinical investigators (CI)
76%55%Percent answering yes
How would you compare TC How would you compare TC (docetaxel/cyclophosphamide) to AC?(docetaxel/cyclophosphamide) to AC?
Antitumor efficacyAntitumor efficacy
20072006
0%0%AC is significantly more efficacious
Clinical investigators (CI)
0%
22%
62%
16%
0%AC is somewhat more efficacious
23%
66%
11%
Both are similar in efficacy
TC is somewhat more efficacious
TC is significantly more efficacious
2007 CI n = 50
How would you compare TC How would you compare TC (docetaxel/cyclophosphamide) to AC?(docetaxel/cyclophosphamide) to AC?
Antitumor efficacyAntitumor efficacy
20072006
1%0%AC is significantly more efficacious
Practicing oncologists (PO)
5%
64%
27%
3%
4%AC is somewhat more efficacious
43%
42%
11%
Both are similar in efficacy
TC is somewhat more efficacious
TC is significantly more efficacious
2007 PO n = 135
20072006
2%0%AC has significantly better safety and tolerability
Clinical investigators (CI)
10%
29%
51%
8%
19%AC has somewhat better safety and tolerability
36%
40%
5%
Both are similar in safety and tolerability
TC has somewhat better safety and tolerability
TC has significantly better safety and tolerability
How would you compare TC How would you compare TC (docetaxel/cyclophosphamide) to AC?(docetaxel/cyclophosphamide) to AC?
Safety and tolerabilitySafety and tolerability
How would you compare TC How would you compare TC (docetaxel/cyclophosphamide) to AC?(docetaxel/cyclophosphamide) to AC?
Safety and tolerabilitySafety and tolerability
20072006
1%1%AC has significantly better safety and tolerability
Practicing oncologists (PO)
8%
32%
48%
11%
7%AC has somewhat better safety and tolerability
36%
49%
7%
Both are similar in safety and tolerability
TC has somewhat better safety and tolerability
TC has significantly better safety and tolerability
2007 PO n = 140
Have you ordered the OncoHave you ordered the Oncotypetype DX™ assay? DX™ assay?
200720062005
75%48%34%Percent answering yes
Practicing oncologists (PO)
Clinical investigators (CI)
98%80% 96%Percent answering yes
If yes, for how many patients?200720062005
14105Mean
Practicing oncologists (PO)
Clinical investigators (CI)
278 15Mean
When the OncoWhen the Oncotypetype DX assay is DX assay is requested for your patients, who requested for your patients, who
generally initiates the order?generally initiates the order?
4%
4%
92%
6%
4%
90%
Other/do not use
Surgeon
Medical oncologist
Clinical investigators Practicing oncologists
If you had breast cancer and were If you had breast cancer and were diagnosed with a 2-cm, ER-positive, diagnosed with a 2-cm, ER-positive,
node-negative tumor with an Onconode-negative tumor with an Oncotypetype DX DX recurrence score in the intermediate range, recurrence score in the intermediate range, how comfortable would you be participating how comfortable would you be participating in the TAILORx study, in which you would in the TAILORx study, in which you would
be randomly assigned to hormonal therapy be randomly assigned to hormonal therapy with or without chemotherapy?with or without chemotherapy?
12%10%Very uncomfortable
19%12%Somewhat uncomfortable
6%
24%
48%
18%
30%
21%
Neutral
Somewhat comfortable
Very comfortable
Clinical investigators Practicing oncologists